Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

clinical investigation of the TLR7 mechanism in HCV by taking ANA773 into a clinical trial under a two-part protocol designed to test ANA773 in both healthy volunteers and patients with HCV. In October, Anadys completed dosing in healthy volunteers. Subjects received a single dose followed by four doses taken every other day, at levels from 200 mg to 1600 mg (with six subjects receiving active and two receiving placebo in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects beginning at 800 mg. Some side effects commonly seen with interferon treatment, including fever and chills, were observed at higher doses, with the frequency and intensity of interferon-like side effects increasing with dose. One subject at the 1200 mg dose and two subjects at the 1600 mg dose discontinued from the trial before completion of dosing. Anadys expects to initiate Part B of the study in HCV patients within the next few weeks. Patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort.

-- Phase I Clinical Trial of ANA773 in Oncology. Anadys continues to enroll patients in an ongoing Phase I clinical trial of ANA773 in oncology and has now completed enrollment in the third cohort.

Webcast of Conference Call

Anadys will host a conference call at 5:00 p.m. EDT today to discuss its third quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 86226986. The webcast and t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/25/2014)... December 25, 2014 The report “Service ... Product Type & Provider Type - Global Advancements, Worldwide ... with an in-depth analysis and forecasting of revenues. ... through 221 pages and in-depth TOC on “Service Quality ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... genetic association studies have uncovered a number of DNA ... these risk variants lie outside of genes, posing a ... cancer. In a report published online today in ... characterized a functional DNA element associated with prostate cancer, ...
... DARTMOUTH, NS , July 12 /PRNewswire/ - Ocean ... EPA/DHA, food and dietary supplement ingredients, announces today the acquisition of ... (GAT) Omega-3 microencapsulation-emulsion technology. , ... As a result of the agreement, ONC acquired the ...
... SEATTLE , July 12 Alaska Airlines ... ), Portland International Airport, Seattle-Tacoma International Airport, ... today announced a strategic initiative to promote aviation biofuel development ... kind in the United States , the "Sustainable Aviation ...
Cached Biology Technology:Prostate cancer risk variant found to be in a functional DNA sequence linked with disease 2Prostate cancer risk variant found to be in a functional DNA sequence linked with disease 3Ocean Nutrition Canada Announces Acquisition of Exclusive License to GAT Food Essentials, Omega-3 Microencapsulation-Emulsion Technology 2Ocean Nutrition Canada Announces Acquisition of Exclusive License to GAT Food Essentials, Omega-3 Microencapsulation-Emulsion Technology 3Transportation and Aviation Leaders Launch Sustainable Biofuels Initiative 2Transportation and Aviation Leaders Launch Sustainable Biofuels Initiative 3
(Date:12/17/2014)... 2014  HITLAB SM announced today its completion of ... adherence to current U.S. Food and Drug Administration (FDA) ... device and smart phone application trials utilizing the highest ... "HITLAB is determined to improve global healthcare access, quality, ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... late spring, the 4000 elk of the Clarks Fork ... the greening grass into the highlands of the Absaroka ... vegetation fed by snowmelt. It,s a short trip (40-60 ... free of roads, fences, metropolitan areas, and other human-built ...
... the first time, researchers investigated enteral nutrition and caloric ... report published in the Journal of the Academy ... showed the value of including registered dietitians in the ... intestine, or enteral route, to critically ill adults has ...
... Higher levels of omega-3 fatty acids in the blood may ... research suggests. Scientists analyzed red blood cell samples from ... hip. The study showed that higher levels of omega-3 fatty ... cells were associated with a lower likelihood of having fractured ...
Cached Biology News:Declining fortunes of Yellowstone's migratory elk 2Declining fortunes of Yellowstone's migratory elk 3Declining fortunes of Yellowstone's migratory elk 4Registered dietitians help critically ill children get necessary nutrition for recovery 2Could a diet high in fish and flax help prevent broken hips? 2Could a diet high in fish and flax help prevent broken hips? 3
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
... Enhancer System is used in ... optimize PCR of problematic and/or ... Enhancer Solution with 10X PCRX ... specificity broader magnesium concentration broader ...
... Clone/PAD: ZMD.473. Immunogen: Synthetic peptide ... the mouse junctophilin-2. Specificity: Specific ... Mouse (positive controls: mouse skeletal muscle ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: ...
Abin-2 (N-16)...
Biology Products: